JOIN NOW!
NEW!
FAQs
Describe the TYK2/STAT Signaling Pathway and Immunologic Rationale for TYK2 Directed Therapy For The Treatment of Psoriasis and Psoriatic Arthritis.
How Does the Selectivity of TYK2 and JAK Enzyme Inhibition Influence Their Safety Profiles
What Is Minimal Disease Activity in PsA and How Does Deucravacitinib Perform at 52 Weeks?
TYK2/STAT Signaling: The Immunologic Rationale for TYK2 Therapy in SLE & Sjögren’s Disease
MEDICATION REVIEWS
What Is the Mechanism of Action of Deucravacitinib?
What is the Safety Profile of Deucravactinib in PsO and PsA?
Deucravacitinib Dosing, Administration, DDIs, & Safety in Clinical Practice
JOURNAL CLUBS
A Review of the Safety and Efficacy of Deucravacitinib or Plaque Psoriasis: an Expert Consensus Panel
Deucravacitinib in Active PsA: 52-Week Efficacy and Safety From POETYK PsA-2
Deep Dive Into Radiographic Progression/Data in PsA From The PsA-1 Manuscript
PODCASTS
Understanding The TYK2/STAT Signaling Pathway in PsA: Clinical Implications and Beyond
Foundations of PMR: Diagnosis, First-Line Therapy, and Tapering Strategies
TYK2 Inhibition in PsA, Sjögren’s and SLE: What APPs Need to Know as Future Uses Emerge